Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

Insmed has secured landmark FDA approval for brensocatib (Brinsupri), making it the first dedicated treatment for non-cystic fibrosis bronchiectasis (NCFBE) and the inaugural drug in the novel dipeptidyl peptidase 1 (DPP1) inhibitor class. Targeting an estimated 500,000 U.S. patients, the oral therapy demonstrated strong efficacy in Phase 3 trials, notably reducing pulmonary exacerbations by 21% with the 10mg dose. Priced at $88,000 annually before discounts, analysts project peak sales reaching up to $6.6 billion, while Insmed has undertaken extensive pre-launch preparations, including engaging nearly all U.S. pulmonologists, and is pursuing international approvals in the EU, UK, and Japan.

Analysis

Insmed has secured a landmark FDA approval for brensocatib (Brinsupri), establishing it as both the first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor and the first-ever approved therapy for non-cystic fibrosis bronchiectasis (NCFBE). This approval targets a significant unmet medical need, with an estimated 500,000 diagnosed patients in the U.S. The decision was based on the Phase 3 ASPEN trial, where the 10mg dose demonstrated a statistically significant 21% reduction in the annual rate of pulmonary exacerbations, a key clinical endpoint. However, the trial was not a complete success, as it failed to meet secondary goals related to reducing severe exacerbations and improving a specific lung function metric for the low dose. Commercially, the drug is priced at $88,000 per year, with Mizuho analysts forecasting peak sales of $6.6 billion, substantially above the company's own $5 billion estimate. The market has reacted with extreme optimism, with Insmed's shares trading up approximately four times since the positive data was released in May 2024. The company's proactive launch strategy, which includes pre-engaging nearly all U.S. pulmonologists since October, is designed to ensure rapid uptake, though analysts anticipate a measured initial ramp with first-year sales projected between $40-$60 million. Insmed is also pursuing global expansion with regulatory submissions underway in the EU and UK, and a planned filing in Japan, targeting potential 2026 launches.

Key Decisions for Investors

• The FDA approval of Brinsupri is a pivotal, de-risking event that transforms Insmed's commercial outlook, establishing a first-in-class asset targeting a substantial market with analyst peak sales projections reaching $6.6 billion.
• Investors should closely monitor the initial commercial launch metrics against Wall Street's first-year sales forecast of $40-$60 million, as execution and physician uptake are now the primary drivers for validating the current valuation.
• Given the stock has quadrupled since the data release, it is crucial to assess whether the current price fully incorporates a successful U.S. launch, with potential further upside contingent on achieving international approvals and outperforming sales expectations.